Gilead, GSK eye bigger PAH market with Phase III combo data
This article was originally published in Scrip
Executive Summary
Gilead Sciences and GlaxoSmithKline reported on 8 September that their drug Letairis (ambrisentan) combined with Eli Lilly's Adcirca (tadalafil) reduced the risk of clinical failure in patients with pulmonary arterial hypertension (PAH) by 50% compared with ambrisentan and tadalafil on their own (p=0.0002), but not without increased safety concerns for PAH patients.
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.